Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients

Kawabata, Shinji; Miyatake, Shin; Nonoguchi, Naosuke; Hiramatsu, Ry; Iida, Kaname; Maeda, Shiro; Yokoyama, Kunio; Doi, Atsushi; Kuroda, Yuzo; Kuroiwa, Toshihiko; Michiue, Hiroyuki; Kumada, Hiroaki; Kirihata, Mitsunori; Imahori, Yoshio; Maruhashi, Akira; Sakurai, Yoshinori; Suzuki, Minoru; Masunaga, Shin Ichiro; Ono, Koji

doi:10.1016/j.apradiso.2009.03.015

Cited by 61 publications

(36 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The principal investigator of this clinical trial published the excellent survival data of 21 cases of newly diagnosed GB treated by BNCT with the MST of www.intechopen.com 15.6 months without TMZ. Moreover additional 20 to 30Gy XRT prolonged the MST up to 23.5 months in 11 cases without TMZ (Kawabata et al 2009b). These strategies were also confirmed by pre-clinical bench works (Barth et al 2004).…”

Section: Resultsmentioning

confidence: 72%

Clinical Study on Modified Boron Neutron Capture Therapy for Newly Diagnosed Glioblastoma

Kawabata¹,

Matsushita²,

Furuse³

et al. 2011

Advances in the Biology, Imaging and Therapies for Glioblastoma

Self Cite

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 72%

Clinical Study on Modified Boron Neutron Capture Therapy for Newly Diagnosed Glioblastoma

Kawabata¹,

Matsushita²,

Furuse³

et al. 2011

Advances in the Biology, Imaging and Therapies for Glioblastoma

Self Cite

View full text Add to dashboard Cite

“…In the clinic, BNCT is used to treat patients with high-grade gliomas, melanomas, liver metastasis of colon adenocarcinomas, malignant melanomas, recurrent tumors of head and neck cancer, multiple liver tumors and oral cancer [20][21][22][23][24][25]. To the best of our knowledge, the effect of BNCT on PAs has not been tested yet, probably because PAs are benign tumors and general boron compounds have relatively low biologically weighted concentrations in PA tumor cells.…”

Section: Discussionmentioning

confidence: 99%

Folate receptor-mediated boron-10 containing carbon nanoparticles as potential delivery vehicles for boron neutron capture therapy of nonfunctional pituitary adenomas

Dai

Cai

Hwang

et al. 2013

Sci. China Life Sci.

View full text Add to dashboard Cite

Invasive nonfunctional pituitary adenomas (NFPAs) are difficult to completely resect and often develop tumor recurrence after initial surgery. Currently, no medications are clinically effective in the control of NFPA. Although radiation therapy and radiosurgery are useful to prevent tumor regrowth, they are frequently withheld because of severe complications. Boron neutron capture therapy (BNCT) is a binary radiotherapy that selectively and maximally damages tumor cells without harming the surrounding normal tissue. Folate receptor (FR)-targeted boron-10 containing carbon nanoparticles is a novel boron delivery agent that can be selectively taken up by FR-expressing cells via FR-mediated endocytosis. In this study, FR-targeted boron-10 containing carbon nanoparticles were selectively taken up by NFPAs cells expressing FR but not other types of non-FR expressing pituitary adenomas. After incubation with boron-10 containing carbon nanoparticles and following irradiation with thermal neutrons, the cell viability of NFPAs was significantly decreased, while apoptotic cells were simultaneously increased. However, cells administered the same dose of FR-targeted boron-10 containing carbon nanoparticles without neutron irradiation or received the same neutron irradiation alone did not show significant decrease in cell viability or increase in apoptotic cells. The expression of Bcl-2 was down-regulated and the expression of Bax was up-regulated in NFPAs after treatment with FR-mediated BNCT. In conclusion, FR-targeted boron-10 containing carbon nanoparticles may be an ideal delivery system of boron to NFPAs cells for BNCT. Furthermore, our study also provides a novel insight into therapeutic strategies for invasive NFPA refractory to conventional therapy, while exploring these new applications of BNCT for tumors, especially benign tumors.

show abstract

“…2). Due to its anionic nature, BSH is thought to preferentially accumulate in brain tumors compared to normal parenchyma because of BBB disruption unique to the tumor [28,47,48], and in contrast to BPA, BSH accumulates passively and not by active transport [23]. Early studies of BSH have noted that boron levels in normal brain are sometimes not even detectable [49].…”

Section: Sodium Borocaptatementioning

confidence: 98%

“…Additionally, BPA may preferentially accumulate in brain tumors compared to normal parenchyma due to a compromised BBB integrity within the tumor vasculature [13]. Since BPA uptake is largely an active process, subpopulations of quiescent cancer cells may have lower BPA uptake, thereby decreasing BNCT efficacy [23].…”

Section: Boronophenylalaninementioning

confidence: 99%

“…Despite the potential of BNCT becoming an alternative (or adjunct) treatment modality for glioblastoma multiforme (GBM) [12][13][14][15][16][17][18][19][20][21][22][23], melanoma brain metastases [12,24], adenocarcinoma liver metastases [25][26][27][28][29][30], hepatocellular carcinoma [31] and recurrent head and neck cancer patients [32][33][34][35][36], only two drugs have been investigated in these BNCT clinical trials: L-boronophenylalanine (BPA) and sodium borocaptate (BSH) [10]. The vast majority of patients diagnosed with the aforementioned malignancies undergo palliative care options.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy

2015

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is a promising cancer therapy modality that utilizes the nuclear capture reaction of epithermal neutrons by boron-10 resulting in a localized nuclear fission reaction and subsequent cell death. Since cellular destruction is limited to approximately the diameter of a single cell, primarily only cells in the neutron field with significant boron accumulation will be damaged. However, the emergence of BNCT as a prominent therapy has in large part been hindered by a paucity of tumor selective boron containing agents. While L-boronophenylalanine and sodium borocaptate are the most commonly investigated clinical agents, new agents are desperately needed due to their suboptimal tumor selectivity. This review will highlight the various strategies to improve tumor boron delivery including: nucleoside and carbohydrate analogs, unnatural amino acids, porphyrins, antibody-dendrimer conjugates, cationic polymers, cell-membrane penetrating peptides, liposomes and nanoparticles.

show abstract

Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients

Cited by 61 publications

References 9 publications

Clinical Study on Modified Boron Neutron Capture Therapy for Newly Diagnosed Glioblastoma

Clinical Study on Modified Boron Neutron Capture Therapy for Newly Diagnosed Glioblastoma

Folate receptor-mediated boron-10 containing carbon nanoparticles as potential delivery vehicles for boron neutron capture therapy of nonfunctional pituitary adenomas

Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy

Contact Info

Product

Resources

About